Study links miR-18a and miR-19a to ERα regulation in CMT cells
Bottom line
Researchers have published new evidence that two microRNAs, miR-18a and miR-19a, can directly reduce reporter activity tied to the estrogen receptor alpha gene, ESR1, in the canine mammary tumor cell line CMT28. In the new Veterinary Sciences paper, Deepika Goyal and Richard Curtis Bird reported that ESR1 mRNA expression was markedly lower in several canine mammary tumor cell lines, including CMT27, CMT28, and CMT47, than in normal canine mammary epithelial cells, while miR-18a and miR-19a were increased to varying degrees across tumor lines. Using luciferase reporter assays, the authors found both microRNAs suppressed activity through predicted binding regions in the canine ESR1 3′UTR, and that effect was lost when those seed-match regions were deleted. Anti-miR constructs reversed the suppression, adding functional support for a direct regulatory role. (mdpi.com)
Why it matters: For veterinary professionals, the study adds a mechanistic layer to a familiar clinical observation: lower ERα expression tends to track with more aggressive canine mammary tumors and poorer outcomes. Prior literature has linked reduced ER expression in canine mammary cancer with shorter disease-free and overall survival, while broader reviews suggest hormone receptor status could help refine prognosis and, eventually, treatment selection. This new work doesn’t change practice now, but it helps explain how ER loss may occur and strengthens the case for microRNAs as future biomarkers, or even therapeutic targets, in canine mammary oncology. (frontiersin.org)
What to watch: The next step is whether these miRNA-ESR1 interactions can be confirmed in primary tumor samples and shown to affect endogenous ERα expression, prognosis, or treatment response in dogs, not just reporter systems in cell lines. (mdpi.com)
Key facts
- Study type
- Mechanistic cell-line study
- Journal
- Veterinary Sciences
- Publication date
- October 10, 2026
- Cell lines studied
- CMT27, CMT28, CMT47, CMT12, and normal canine mammary epithelial cells
- Main finding
- miR-18a and miR-19a suppressed reporter activity through predicted binding sites in the canine ESR1 3′UTR
- Validation method
- Luciferase reporter assays
- Functional support
- Anti-miR-18a and anti-miR-19a increased reporter activity
- Expression pattern
- ESR1 mRNA was much lower in CMT27, CMT28, and CMT47 than in normal canine mammary epithelial cells
A newly published study in Veterinary Sciences points to a specific post-transcriptional mechanism that may help explain why estrogen receptor alpha, or ERα, is lost in some canine mammary tumors. In the October 10, 2026 paper, Deepika Goyal and Richard Curtis Bird reported that miR-18a and miR-19a can suppress reporter activity through predicted binding sites in the canine ESR1 3′UTR in CMT28 cells, offering functional evidence that these microRNAs may help regulate ERα signaling in canine mammary cancer. (mdpi.com)
That question matters because ER status has long carried prognostic weight in canine mammary oncology. Reviews and older clinical pathology studies have shown that ER expression is generally higher in normal mammary tissue, dysplastic tissue, and benign tumors than in malignant tumors, and lower ER expression has been associated with larger tumors, lymph node involvement, metastasis, and worse survival outcomes. More recent reviews continue to describe ER-positive tumors as more common in lower-grade disease, while high-grade carcinomas more often lose hormone receptor expression as tumors become less hormonally dependent. (frontiersin.org)
In the new study, the authors first measured ESR1 mRNA, miR-18a, and miR-19a across canine mammary cell lines. They found ESR1 mRNA was much lower in CMT27, CMT28, and CMT47 than in normal canine mammary epithelial cells, while CMT12 showed higher ESR1 expression. Bioinformatic analysis identified predicted seed-match sites for miR-18a and miR-19a in the canine ESR1 3′UTR. In luciferase reporter assays, both microRNAs significantly reduced reporter activity when the relevant ESR1 3′UTR regions were present, but not when the predicted binding regions were deleted. Anti-miR-18a and anti-miR-19a also increased reporter activity compared with the microRNAs alone. The authors said the findings provide functional evidence of regulation through selected ESR1 3′UTR regions, while also noting that more work is needed to determine whether the same mechanism drives endogenous ESR1 expression in tumors. (mdpi.com)
The study also fits with a growing body of canine mammary tumor epigenetics research. Earlier work has linked miR-18 family upregulation with decreased ESR1 expression and reduced ERα immunoexpression in highly proliferative canine mammary carcinomas, and exosomal microRNA studies have flagged miR-18a as a high-likelihood regulator of ESR1-related pathways. At the same time, translational oncology reviews continue to position naturally occurring canine mammary tumors as a useful comparative model for human breast cancer, especially for studying hormone receptor biology and progression from hormone-responsive to more aggressive phenotypes. (pmc.ncbi.nlm.nih.gov)
There doesn’t appear to be a separate institutional press release or broad industry reaction yet, which isn’t unusual for an early mechanistic cell-line paper. Still, the findings line up with the field’s wider interest in microRNAs as biomarkers and biologic drivers of canine mammary disease. Reviews of current canine mammary tumor biomarkers have suggested that hormone receptor profiling, paired with emerging molecular markers such as miRNAs, could eventually improve prognostic stratification and identify dogs more likely to benefit from targeted approaches, though that work remains early. (link.springer.com)
Why it matters: For practicing veterinarians, this is not a practice-changing paper today. It doesn’t validate a new diagnostic assay, establish a treatment protocol, or show clinical benefit in patients. What it does offer is a more precise explanation for a clinically relevant pattern: why some canine mammary tumors may lose ERα expression as they become more aggressive. If future studies confirm that miR-18a and miR-19a influence endogenous ESR1 expression in patient tumors, these molecules could become part of a more refined biomarker framework for prognosis, case stratification, and possibly endocrine-therapy decision-making in veterinary oncology. That’s especially relevant because ER status in dogs, much like in human breast cancer, may help distinguish tumors that remain hormonally driven from those that have shifted toward more treatment-resistant biology. (frontiersin.org)
What to watch: The key next steps are validation in primary canine mammary tumor tissues, correlation with ER immunostaining and outcomes, and testing whether blocking these microRNAs changes endogenous ESR1 expression or tumor behavior in more clinically relevant models. If those data emerge, the work could move from mechanistic insight toward translational relevance for veterinary diagnostics and oncology care. (mdpi.com)